Opioid Withdrawal’s Potential CV Risk Drives Advisory Panel For Constipation Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA seeks advisory committee’s advice on whether cardiovascular outcomes trials for peripherally active mu opioid receptor antagonists should be required and the timing of any such studies.